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The aim of the study was to determine the maximum-tolerated dose and dose-limiting toxicities for BMS-184476, in combination
with carboplatin, in patients with advanced solid tumours and to describe any preliminary antitumour activity associated with this
regimen. Patients received combination therapy with BMS-184476 given intravenously over 1h followed by carboplatin administered
over 30min on day 1 of a 21-day cycle. In all, 28 patients received 146 cycles of BMS-184476 and carboplatin. Patients were enrolled
at four dose levels: BMS-184476 (mgm
 2)/carboplatin (mgminml
 1): 40/5, 50/5, 50/6 and 60/6. Dose-limiting toxicity at 60/6 was
neutropenia. Among 27 evaluable patients, 11 demonstrated stable disease for a median of 8.5 cycles. In 22 patients, the
pharmacokinetics of BMS-184476 appeared independent of dose of BMS-184476. The mean7s.e.m. values for clearance (Cl),
volume of distribution at steady state and apparent terminal half-life of BMS-184476 in the four dose groups during cycle 1 were
192725mlminm
 2, 377769lm
 2 and 33.775.9h, respectively. An increase in the dose of carboplatin from 5 to 6mgminml
 1
may have decreased Cl of BMS-184476. BMS-184476 in combination with carboplatin was well tolerated at a dose of 50/6 and
shows evidence of antitumour activity in a pretreated population.
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BMS-184476 is a novel taxane, characterised by the substitution of
a 7-methylthiomethyl ether group for the 7-hydroxyl group found
on paclitaxel (Altstadt et al, 2001). BMS-184476 was developed to
counter two common mechanisms of paclitaxel resistance:
elimination through the P-glycoprotein efflux pump and resistance
through tubulin mutations. BMS-184476 demonstrated greater
activity than paclitaxel in a P-glycoprotein 170-mediated multi-
drug-resistant cell line as well as in the A2780/tax cell line (Rose
et al, 2001). There has also been encouraging antitumour activity
in human xenograft tumour models (Rose et al, 2001). The 7-
methylthiomethyl ether substitution increases the solubility of the
drug and reduces the amount of Cremophor EL
s required as
diluent. However, it is not clear as to whether these changes in
formulation have resulted in less hypersensitivity and neurotoxi-
city than seen with commercially available taxanes.
Two phase I studies of BMS-184476 given as a single agent have
been published. Hidalgo et al (2001) treated 34 patients at doses
ranging from 20 to 80mgm
 2, every 21 days. Dose-limiting
toxicities (DLTs) of neutropenia, febrile neutropenia, diarrhoea
and mucositis established a maximum-tolerated dose (MTD) of
60mgm
 2. Plummer et al (2002) have reported results of a second
phase I study in which BMS-184476 was given weekly for 3
consecutive weeks, every 28 days, although this schedule was later
amended to a modified schedule of days 1 and 8 dosing every 21
days. In 53 treated patients, neutropenia emerged as the DLT and
diarrhoea was a common nonhaematologic toxicity. These authors
recommended a phase II dose of 50mgm
 2 on days 1 and 8 of 21-
day cycle.
We conducted a phase I trial of BMS-184476 in combination
with carboplatin on day 1 of a 21-day cycle. Combination regimens
incorporating a taxane with a platinum salt are widely used in the
treatment of solid tumours such as ovarian cancer, non-small-cell
lung cancer (NSCLC) and other solid tumours. We investigated the
pharmocokinetic profile of BMS-184476 in combination with
carboplatin, and report preliminary evidence of antitumour
activity of the combination. The goals of the study were to
characterise the toxicities of the combination and to define the
appropriate dose for phase II studies.
MATERIALS AND METHODS
Patient population
Adult patients were eligible for this study if they had a
histologically confirmed advanced solid malignancy. Patients were
required to have either measurable or evaluable disease, an ECOG
performance status of p2 and at least 4 intervening weeks since
their last prior treatment (or 6 weeks for drugs with delayed
toxicity). Enrolment was also conditional upon adequate end-
organ function, defined by the corresponding laboratory values: an
absolute granulocyte count X1500mm
 3, platelet count
X100000mm
 3, serum bilirubin p2.0mgdl
 1; serum AST and
ALT p2.5 times institutional upper limits of normal (p5-fold the
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linstitutional upper limit of normal for patients with liver
metastases) and serum creatinine p1.5 times the institutional
upper limit of normal (or measured or calculated creatinine
clearance (Cl) X60mlmin
 1). All toxicity related to prior
treatment was required to have recovered to baseline or pGrade
1. The exclusion criteria included a history of severe hypersensi-
tivity reactions (HSRs) to agents containing Cremophor EL
s
(polyoxyethylated castor oil), pre-existing neurologic toxicity
greater than Grade 1 and active brain metastases.
This study was approved by the Institutional Review Board of
the University of Pennsylvania and all enrolled patients provided
written informed consent.
Treatment plan
BMS-184476 was supplied in a 5ml vial as a 15mgml
 1 solution,
in conjunction with a second vial containing aqueous Cremophor
EL
s solution as diluent. The solution was further diluted with
250cm
3 5% dextrose or 0.9% sodium chloride. BMS-184476 was
administered intravenously (i.v.) by infusion pump over 1h on day
1 of 21-day cycle. Within an hour after completion of the BMS-
184476 infusion, carboplatin was administered over 30min.
The treatment protocol was amended to include routine
hypersensitivity prophylaxis after reactions were noted in four of
the first 17 subjects treated. This regimen consisted of diphenhy-
dramine 50mg, dexamethasone 10mg and cimetidine 300mg
given i.v. 30min prior to BMS-184476 administration.
Patients experiencing a DLT could remain on study upon
recovery from toxicity to baseline or pGrade 1. For patients with
Grade 4 neutropenia lasting 5 or more days or febrile neutropenia,
the BMS-184476 dose was decreased by one level (dose levels  1
and  2 were 30 and 25mgm
 2, respectively) with a concomitant
dose reduction in carboplatin of 50%.
The carboplatin infusion was prepared from commercially
available vials containing sterile aqueous solution, which were
diluted with 5% dextrose injection or 0.9% sodium chloride
injection. After antiemetic prophylaxis, which included a 5-HT3
inhibitor, carboplatin was given as a 30-min i.v. infusion on day 1
of the 21-day cycle. Antiemetic prophylaxis and treatment were
employed, including a 5-HT3 antagonist, dexamethasone and
metoclopramide.
Colony-stimulating factors were not administered prophylacti-
cally, but could be used at the discretion of the treating physician
in the event of febrile neutropenia. Prophylactic and therapeutic
use of erythropoietin was permitted.
Table 1 summarises the dose escalation schedule administered,
with the corresponding number of patients treated. Dose escala-
tions were based on the occurrence of DLTs in the first cycle of
treatment, defined as drug-related adverse events and graded
according to the National Cancer Institute Common Toxicity
Criteria 2.0. DLTs were defined as: absolute neutrophil count
(ANC) o500mm
 3 for X5 consecutive days or febrile neutrope-
nia; platelet count o25000mm
 3 or Grade 3/4 thrombocytopenia
requiring transfusion; Grade 3/4 nausea and vomiting despite
appropriate medical intervention; any other Grade 3/4 nonhaema-
tologic toxicity except: fatigue/asthenia and transient arthralgia/
myalgia.
If a DLT was observed in zero of three patients at a dose level,
escalation to the next dose level was permitted. If a DLT was
observed in one of the first three subjects at a dose level, three
additional patients were treated at that level. If two or more
subjects experienced a DLT at a dose level, that dose level was
deemed the maximum dose level to be tested. If a DLT occurred,
repeated cycles could be delayed for up to 14 days.
Patients with stable disease or response to therapy were
continued on therapy. Responses were evaluated according to
World Health Organization (WHO) criteria (World Health
Organization, 1979).
Patient monitoring
On the day of therapy, a medical history, physical examination,
complete blood count (CBC), biochemical profile, electrocardio-
gram, urinalysis and chest X-ray were performed. Patients were
subsequently monitored by twice weekly CBCs and weekly
biochemical profiles. Patients with documented myelosuppression
were followed by CBCs every 2 days until recovery. Physical
examination as well as appropriate imaging procedures to assess
the response of the patient’s disease were performed and repeated
every other course.
Sample collection and analysis
Serial blood samples were collected predose and at 0.5, 1, 1.25, 1.5,
2, 2.5, 3, 4, 6, 24, 48 and 72h after the start of the 1-h infusion of
BMS-184476. Blood samples (5ml) were collected from a
peripheral vein, from a site contralateral to the BMS-184476
infusion. Within 1h of collection, the plasma was separated by
centrifugation at approximately 1000r.p.m. for 15min at 41C.
Plasma was stored at or below  201C until analysis.
Plasma samples were analysed for concentrations of BMS-
184476, its sulphoxide metabolites (BMS-246178 and BMS-246180),
and paclitaxel by a validated HPLC method (Bristol-Myers Squibb
Pharmaceutical Research Institute, Princeton, NJ, USA). The
criteria for acceptance of an analytical run specified that the
deviation of the predicted concentrations from the nominal
concentrations for at least three-fourths of all calibration standards
for an analyte and at least two-thirds of all quality control samples
for an analyte be within 715%. After the addition of internal
standard, BMS-183061, to 1.0ml of plasma, the sample was
vortexed and loaded onto an unendcapped Cyano (CN-U) solid-
phase extraction column (Varian, Harbor City, CA, USA). The
compounds were eluted with 0.1% formic acid in methanol, the
eluent was evaporated to dryness and the residue was recon-
stituted. Chromatographic separation of the compounds was
achieved on a Zorbax RX-C18, 5mm, 4.6 250mm
2 column
(Hewlett Packard Co., Wilmington, DE, USA) using a mobile
phase consisting of 51.5% acetonitrile in water containing
10mmoll
 1 ammonium acetate (pH titrated to 5.0 with acetic
acid) and 10mmoll
 1 tetramethlammonium hydroxide (pH
titrated to 5.0 with acetic acid) at 401C. The flow rate was
1.0mlmin
 1. Detection was by ultraviolet absorbance at 227nm.
The lower limit of quantitation of the assay was 9.14ngml
 1 for
BMS-184476, 4.65ngml
 1 for BMS-246178, 4.65ngml
 1 for BMS-
246180 and 8.54ngml
 1 for paclitaxel.
Pharmacokinetic and pharmacodynamic analyses
Estimates of pharmacokinetic parameters for BMS-184476 were
derived from individual concentration–time data sets by non-
compartmental analysis methods performed using the PKMENU
application written in SAS version 6.12. (SAS, Cary, NC, USA)
(Gibaldi and Perrier, 1982). The values of the maximum plasma
Table 1 Dose escalation schema
Dose level
BMS-184476
(mgm
 2)
Carboplatin AUC
(mgminml
 1)
No. of
patients
14 0 5 7
25 0 5 6
3
a 50 6 13
46 0 6 2
aDose level expanded after MTD established at dose level 4. MTD¼maximum-
tolerated dose
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lconcentration (Cmax) were recorded directly from experimental
observations. The area under the plasma concentration vs time
curve from time zero to the time of the last measurable
concentration T (AUC0–T) was calculated using a combination of
linear and log trapezoidal summations. The first-order rate
constant of decline of BMS-184476 concentrations in the terminal
phase of the plasma concentration–time data set, l, was estimated
by log-linear regression, using no weighting factor, of at least three
data points yielding a minimum mean square error. The absolute
value of l was used to estimate the apparent terminal elimination
half-life (t1/2). The last measurable concentration and the rate
constant, l, were used to extrapolate the AUC0–T to estimate the
area under the curve from time zero to infinity (AUC0–N). The
total body Cl was calculated by dividing the dose by AUC0–N. The
volume of distribution at steady state (VSS) was calculated using
standard noncompartmental methods.
The relationships between BMS-184476 systemic exposure and
toxicity as indicated by the percentage of decrease in the ANC were
explored. The percentage of decrease in ANC was calculated as
follows, for cycle 1:
%DecreaseinANC ¼100 ðpost-treatmentnadircount
  pretreatmentcountÞ=ðpretreatmentcountÞ
The relationship between BMS-184476 AUC0–N and the percen-
tage of decrease in the ANC was evaluated using Kinetica 4.0.2
(InnaPhase Corporation, Philadelphia, PA, USA). Discrimination
between pharmacodynamic models was guided by minimisation of
the weighted sum of squares and standard errors for the
pharmacodynamic parameters, examination of the dispersion of
the residuals and use of the objective function, Akaike criteria and
Schwartz criteria.
RESULTS
Patient characteristics
The demographic characteristics for patients entered on this study
are shown in Table 2. In all, 28 patients with a median age of 60
years were enrolled (range 33–78 years). Patients varied with
respect to previous therapy and 11 had no prior chemotherapy or
radiation. A total of 146 cycles of BMS-184476 and carboplatin
were given, for a median of two per patient (range 1–25).
Dose-limiting toxicity
Patients were enrolled at four combination dose levels, sum-
marised in Table 1. At the first dose level, one of six patients
experienced Grade 4 neutropenia in the first cycle that lasted X5
days, representing a DLT. This patient had melanoma and was
previously treated with dacarbazine, cisplatin, carmustine, and
tamoxifen (so-called ‘Dartmouth regimen’). Dose escalation
continued when no additional DLTs occurred at this dose level.
No DLTs were observed in the second and third dose levels,
initially. At the fourth dose level, both patients treated demon-
strated DLTs of neutropenia lasting X5 days. A 74-year-old patient
man with NSCLC and no prior therapies experienced Grade 4
neutropenia in cycle 1 and went off study. A 76-year-old female
with NSCLC and no prior therapies also experienced Grade 4
neutropenia in cycle 1. This patient remained on study for an
additional eight cycles, despite Grade 3 or 4 neutropenia in each,
after appropriate delay and dose modification, without complica-
tion. These DLTs halted the dose-escalation portion of the study.
Subsequent expansion of the third dose level resulted in two
additional DLTs, described below.
Haematologic toxicity
Haematologic toxicity was seen commonly in patients at all dose
levels, in the first cycle of treatment and in subsequent cycles.
Table 3a summarises results from cycle 1. At the second dose level,
Grade 3 neutropenia was seen in three of six patients. No episodes
of Grade 4 neutropenia were seen in the first six patients at the
third dose level.
The first two patients entered on the fourth dose level
experienced dose-limiting neutropenia, as described above, halting
the escalation phase of the study. Upon expanding the third dose
level, four of seven patients demonstrated Grade 4 neutropenia,
although two of these episodes lasted less than 5 days and were not
considered DLTs. Two patients experienced neutropenia, meeting
the criteria for DLT. The first of these was a 52-year-old man with
mesothelioma and one prior course of chemotherapy who suffered
no febrile or infectious complications. The second was a 56-year-
old female with NSCLC and no prior treatments who went on to
receive seven additional cycles of therapy at modified doses.
As illustrated in Table 3b, there appeared to be some cumulative
haematologic toxicity. Grade 4 neutropenia was seen at all dose
levels and reported in a total of 37 of 149 cycles administered; 24 of
these episodes occurred in the 13 patients treated at the third dose
level.
Nonhaematologic toxicity
There were no instances of Grade 3 or 4 nonhaematologic toxicity
in the first cycle. Fatigue, nausea, vomiting and diarrhoea were
common, although of manageable severity (Table 4). When
subsequent cycles were considered, one episode of Grade 4
vomiting was reported in a patient with advanced pancreatic
cancer. An episode of Grade 4 gastrointestinal bleeding, which was
deemed to be disease related, was reported in a patient with
advanced colon cancer. Sensory neuropathy was reported by four
patients and limited to Grade 1 during 16 cycles. Motor
neuropathy was reported by two patients and described as Grade
1 in three cycles and Grade 2 in two cycles. No trend of cumulative
Table 2 Patient characteristics
n
Entered/evaluable 28/27
Male/female 15/13
Median age (range) 60 (33–78)
Performance status
01 7
11 1
Primary tumour site
Lung (NSCLC) 12
Colon 3
Gastric 3
Adenoidcystic 2
Melanoma 2
Mesothelioma 2
Biliary tract 1
Ovary 1
Pancreas 1
Peritoneal 1
Sarcoma 1
Prior treatment
Previous chemotherapy 11
Previous radiation 1
Previous chemotherapy and radiation 4
No Previous chemotherapy or radiation 12
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lneurotoxicity was apparent in these patients. Eight patients
reported alopecia that was limited to Grade 2. Grade 1 arthralgias
and myalgias were reported in 10 and two cycles, respectively.
One patient at dose level 1 experienced a Grade 2 HSR in his
second cycle of treatment. A second patient at dose level 2
developed a Grade 2 HSRs in the first cycle of treatment. A third
patient treated at dose level 2 developed Grade 2 hypersensitivity
during the first two cycles of treatments. A fourth patient treated at
dose level 3 demonstrated a Grade 1 HSR during cycle 1 and a
Grade 2 HSR during cycle 2. No additional episodes were seen after
the implementation of a prophylactic regimen consisting of
diphenhydramine 50mg, dexamethasone 10mg and cimetidine
300mg given i.v. 30min prior to the BMS-184476 infusion.
Patient benefit
A total of 11 patients demonstrated stable disease as their best
response. They included patients with NSCLC (6), colon (1), gall
bladder (1), gastric (1) and ovarian (1) cancers and melanoma (1).
Patients with stable disease received a median of 8.5 cycles (range:
4–25). A patient with NSCLC and no previous therapy was treated
at the first dose level and received 25 cycles of therapy over 18
months. Two other patients with NSCLC, both without prior
therapy, exhibited stable disease for 14 cycles each. None of the six
NSCLC patients exhibiting stable disease had received prior
therapy.
Pharmacokinetics and pharmacodynamics
Evaluable plasma concentration–time profiles were obtained from
22 patients during the first cycle of treatment; one patient at the
60/6 dose level had no samples collected and one patient at the 40/
5 dose level, one patient at the 50/5 dose level and four patients at
the 50/6 dose level were excluded from pharmacokinetic evaluation
because an insufficient number of samples were collected to permit
a reliable analysis. Plasma concentrations were quantifiable in all
patients through 48–72h (Table 5).
The mean (s.d.) plasma concentration–time profiles of BMS-
184476 are shown in Figure 1 and mean BMS-184476 pharmaco-
kinetic parameters are listed in Table 6. The pharmacokinetics of
BMS-184476 appeared independent of the dose of BMS-184476.
The mean7s.e.m. values for Cl, volume of distribution at steady
state and apparent terminal half-life of the four dose groups during
cycle 1 were 192725mlminm
 2, 377769lm
 2 and 33.775.9h,
respectively. Cl of BMS-184476 was compared at carboplatin doses
of 5 and 6mgminml
 1, with mean7s.d. values of 215754
(n¼11) and 177767mlminm
 2 (n¼11), respectively. This
difference did not achieve statistical significance (P¼0.15). At
the recommended phase II dose of 50/6, interpatient variability in
Table 3 (a) Haematologic toxicity during cycle 1 and (b) worst haematologic toxicity (all cycles)
Neutropenia Thrombocytopenia
Dose level No. of patients 01234 0 1 2 3 4
(a) Haematologic toxicity
17 4 — 1 1 1 6 — — 1 —
2 6 — 3 —3 —5 1———
31 3 1 3 2 3 4
a 1 2 1———
4 2 — — — —2 —————
(b) Worst haematologic toxicity
14 0 2 3 4 9 3 1 2 7 1 1 — 1 —
2 1 6 — 41 7 48 71— —
3 75 11 5 11 24 24 51 20 2 2 —
4 1 5 3 — — 4 85 82— —
aLasted o5 days in two patients. Two DLTs seen after dose expansion.
Table 4 Nonhaematologic toxicity (cycle 1)
Fatigue Nausea Vomiting Diarrhoea
Dose level No. of patients 0 1 2 3 012301230123
1 7 41 2—2 3 2— 34—— 52——
2 6 3 —3—3 2 1— 32 1— 5—1—
3 1 3 7 42 — 661 — 1 2 —1— 1 03— —
4 2 1 1 ——————————————
Table 5 Worst selected nonhaematologic toxicities (per course)
No. of courses (%)
01 2 3 4
Fatigue 86 30 29 1 —
Nausea 95 42 8 1 —
Alopecia 110 19 17 — —
Constipation 121 10 15 — —
Diarrhoea 127 14 5 — —
Vomiting 128 14 4 — 1
Sensory neuropathy 130 16 — — —
Peripheral oedema 133 13 — — —
Arthralgia 136 10 — — —
Anorexia 138 6 1 1 —
Hypersensitivity 139 2 5 — —
Motor neuropathy 141 3 2 — —
GI bleeding 143 2 — — 1
Myalgia 144 2 — — —
Stomatitis 144 2 — — —
Rash 145 1 — — —
Tinnitus 145 1 — — —
Nystagmus 145 1 — — —
Hand–foot 145 1 — — —
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lthe principal pharmacokinetic parameters was moderate, with
coefficients of variation percentages of 40, 56 and 43 for CL, VSS
and t1/2, respectively, and there was a 4.2-fold range of AUC0–N
values. The relationship of Cmax or AUC0–N to a dose of BMS-
184476 could not be evaluated because of the limited range of
doses administered with either 5 or 6mgminml
 1 of carboplatin.
The metabolites BMS-246178, BMS-246180 and paclitaxel were
sporadically quantifiable with concentrations much less than BMS-
184476.
A scatter plot of the pharmacodynamic relationship between the
percentage of decrease in ANC during course 1 and the BMS-
184476 exposure as determined by the AUC0–N is shown in
Figure 2. The relationship in this study was not well described by
models of drug action, including linear, log linear, Emax or sigmoid
Emax.
DISCUSSION
Dose-limiting toxicity of neutropenia was seen at the highest dose
level planned for this study, at doses of BMS-184476 60mgm
 2
and carboplatin AUC of 6mgminml
 1. An expansion of the
penultimate dose level – BMS-184476 50mgm
 2 and carboplatin
AUC of 6mgminml
 1 – revealed two additional DLTs and two
other episodes of Grade 4 neutropenia, not meeting the criteria for
DLT in cycle 1. These Grade 4 adverse events did not occur in
heavily pretreated patients. Moreover, some cumulative myelo-
toxicity was observed in the 13 patients treated at the expanded
dose level (Table 3b). For these reasons, we recommend that
further study of this combination in the phase II setting should
begin at dose of BMS-184476 50mgm
 2 and carboplatin AUC of
6mgminml
 1, with the recognition that intraindividual dose
modification may be required as the number of cycles increase.
The non-haematologic toxicities we observed for this combina-
tion were similar to those previously reported for BMS-184476
given alone and in combination. Febrile neutropenia, diarrhoea
and/or mucositis were dose limiting at doses of 70 and 80mgm
 2
given every 3 weeks in the single-agent study reported by Hidalgo
et al (2001). One of 15 patients treated at 60mgm
 2 (deemed the
MTD) exhibited Grade 4 febrile neutropenia and Grade 3
diarrhoea. A second phase I study of an alternative dosing
schedule, in which BMS-184476 was given on days 1 and 8 of 21-
day cycle, also revealed unacceptable neutropenia at doses
exceeding 50mgm
 2 (Plummer et al, 2002). A combination study
of BMS-184476 and doxorubicin reported three DLTs of neutro-
penia at doses of doxorubicin 50mgm
 2 and BMS-184476 at
40mgm
 2 given every 3 weeks, prompting the investigation of
other dosing schedules (Sessa et al, 2001). Our group recently
reported results of a phase I study of BMS-184476 given in
combination with cisplatin given every 3 weeks. Grade 4
neutropenia was seen in three of 18 patients in cycle 1, at doses
of BMS-184476 60mgm
 2 and cisplatin 75mgm
 2. In the BMs-
184476/cisplatin study, diarrhoea, nausea and vomiting also met
the criteria for DLTs. The toxicities were substantially less in the
carboplatin combination and full doses of both BMS-184476 and
carboplatin could be administered to most patients. Thus, the
combination of BMS-184476 and carboplatin caused a similar
degree of neutropenia at comparable BMS-184476 doses tested in
single-agent studies (Hidalgo et al, 2001; Plummer et al, 2002). The
addition of carboplatin did not appear to increase this toxicity
profile. Moreover, the incidence and severity of thrombocytopenia
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Figure 1 Mean concentration–time profiles of BMS-184476 after the
administration of BMS-184476 (mgm
 2)/carboplatin (mgminml
 1)a t
dose levels of 40/5 (B), 50/5 (,), 50/6 (J), 60/6 (&). Error bars indicate
standard deviation.
Table 6 Pharmacokinetic parameters of BMS-184476 in patients during cycle 1
a
Dose group
b No. of patients Cmax (ngml
 1) AUC0-N (hngml
 1) Cl (mlminm
 2) t1/2 (h) VSS (lm
 2)
40/5 6 15667874 34137920 212773 33.6715.6 3887231
50/5 5 14157414 37767429 218722 28.9711.9 3617152
50/6 9 196471255 550772791 181773 43.2718.6 4767266
60/6 2 1545
c 6613
c 155
c 28.8
c 284
c
aValues are the mean7s.d.
bBMS-184476 (mgm
 2)/carboplatin (mgminml
 1).
cs.d. not presented because n¼2.
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Figure 2 Scatter plot showing the relationship between BMS-184476
AUC0–N and the percentage of decrease in ANC during course 1 (K).
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lobserved at all dose levels was low, suggesting that BMS-184476
may provide the same platelet sparing effects as taxol, when
combined with carboplatin (Belani et al, 1999).
At the initiation of this study, a premedication regimen for the
prevention of HSR was not given, in light of reports from single-
agent trials and the expectation that lower Cremophor EL content
would markedly decrease the incidence of such reactions.
However, four patients developed pGrade 2 hypersensitivity
reactions in our study, prompting the administration of a
prophylactic premedication regimen. A regimen consisting of i.v.
diphenhydramine 50mg, dexamethasone 10mg and cimetidine
300mg prevented additional HSRs in the patients with previous
episodes and in previously untreated patients. Although HSRs may
be less frequent and less severe than with paclitaxel, we
recommend that prophylactic premedication for all patients in
future studies of BMS-184476.
The pharmacokinetics of BMS-184476 combined with
5mgminml
 1 of carboplatin in this study were similar to those
of BMS-184476 given as a single agent and were characterised by a
large volume of distribution and a long apparent terminal
elimination half-life (Plummer et al, 2002). Although there is
some indication that the increase of dose of carboplatin from 5
to 6mgminml
 1 may have resulted in a decreased CL of
BMS-184476, the difference is not statistically significant. Also,
there was no indication that carboplatin affected the metabolism
of BMS-184476 to its sulphoxide metabolites (BMS-246178 and
BMS-246180) or paclitaxel. The pharmacokinetics of BMS-184476
in combination with carboplatin in this study appeared linear as
was observed for BMS-18476 as a single agent (Plummer et al,
2002). This is in contrast to the nonlinear pharmacokinetic
behaviour of paclitaxel (Gibaldi and Perrier, 1982; Henningsson
et al, 2001).
In this study of BMS-184476 combined with carboplatin,
the relationship during course 1 between haematologic toxicity
as determined by the percentage of decrease in ANC and the
BMS-184476 exposure as determined by the AUC0–N was not well
described by several models of drug action. In a previous study of
BMS-184476 as a single agent, the relationship was well described
by a sigmoid Emax model (Rose et al, 2001). The lack of fit to a
sigmoid Emax model might be explained by the narrower dose
range in this study (40–60mgm
 2) as compared to the previous
study (20–80mgm
 2) that resulted in a narrower range of
exposure. However, the relationship might then be expected to
be described by a linear or log-linear model. Another possible
explanation is that the AUC0–N of BMS-184476 alone is not
adequate to describe the decrease in ANC when BMS-184476 is
combined with carboplatin.
Patient benefit was limited to stable disease in 11 patients. Six of
these had NSCLC that had not been previously treated. When
achieved, stable disease appeared fairly durable, with patients
receiving a median of 8.5 cycles (range: 4–25). Six of the patients
carried diagnoses of NSCLC, all previously untreated. Three
NSCLC patients also remained on therapy for the greatest number
of cycles, for 25, 14 and 14 cycles, respectively.
In summary, we demonstrated that a combination regimen of
BMS-184476 at 50mgm
 2 and carboplatin AUC of 6mgminml
 1
given on day 1 of a 21-day cycle had a manageable toxicity profile,
with neutropenia representing the most frequent adverse event.
Durable stable disease in six patients with NSCLC justify further
study of this regimen in this population.
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